Terumo (TYO:4543) subsidiary MicroVention announced today that it filed a second lawsuit against Balt USA for trade secret misappropriation. Aliso Viejo, Calif.-based MicroVention’s second lawsuit against Balt and four former employees follows an earlier patent lawsuit that is still ongoing, having been filed in July 2019, according to a news release. MicroVention alleges that, during the discovery […]
Balt
Cerus Endovascular and Balt partnered to deliver Contour Neurovascular System in Germany
Cerus Endovascular and Balt this week announced a strategic distribution agreement to provide AB Medica with the exclusive rights to market and sell the Countour Neurovascular System and the Neqstent Coil Assisted Flow Diverter devices. The distribution agreement is currently limited to Germany. The financial details of the deal were not disclosed. “Our partnership with […]
Balt receives CE Mark for flow diverting shunt
Balt announced that it received CE Mark approval for its Silk Vista flow diverting stent for treating patients with unruptured intracranial aneurysms. Montmorency, France.-based Balt designed its Silk Vista device for predictable and accurate deployment and high visibility under angiography, adding to its already-CE-Marked Silk Vista baby flow diverter, which has been approved in Europe […]
Balt wins IDE approval to start STEM trial
Balt announced that it received FDA investigation device exemption (IDE) for its trial for the treatment of chronic sub-dural hematoma. The Squid trial for the embolization of the middle meningeal artery (STEM) is a prospective, randomized controlled trial for Balt’s Squid liquid embolic device as a minimally invasive treatment option for the neurological disease. Irvine, […]
Judge tosses most of Neurvana case against Balt execs
A Delaware chancery court judge has tossed nearly all of the claims brought by Neurvana Medical against a pair of senior executives of Balt International for reneging on a $16 million deal for Neurvana’s Titan neurovascular catheter. The story of the lawsuit, filed in January 2019, begins with Balt’s September 2016 acquisition of Blockade Medical, including […]
Balt parent escapes Neurvana Medical sabotage suit
Balt International this week escaped a lawsuit brought by Neurvana Medical accusing Balt, its U.S. subsidiary and two executives of reneging on a $16 million deal for its Titan neurovascular catheter in scheme to “sabotage and destroy” Neurvana. In September 2016, the French company acquired Blockade Medical, including its Barricade coil and a facility in Irvine, […]
Balt wins CE Mark for Titan aspiration catheter
Balt said yesterday that it won CE Mark approval in the European Union for the Titan aspiration catheter. The catheter dates back to the September 2016 acquisition of endovascular device developer Blockade Medical and its Barricade coil. Blockade’s facility in Irvine, Calif., became the headquarters for Balt’s new American subsidiary, with Blockade co-founder, president & […]
Neurvana Medical alleges Balt sought to ‘sabotage and destroy’ after spinout
Neurvana Medical this month accused Balt International and a pair of its senior executives of reneging on a $16 million deal for its Titan neurovascular catheter in scheme to “sabotage and destroy” Neurvana. The story of the lawsuit, filed Jan. 17 in the Delaware Chancery Court, begins with Balt’s September 2016 acquisition of Blockade Medical, including its Barricade […]
7 medtech stories we missed this week: March 23, 2018
From Medizone’s evaluation deal to Advantis Medical Imaging getting CE Mark approval, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. Medizone inks AsepticSure evaluation deal with commercial cleaning products maker Innovasource Medizone announced in a March 22 press release that it has signed a product evaluation agreement with […]
Balt International buys Blockade Medical
European medtech firm Balt International said today it acquired endovascular device developer Blockade Medical for an undisclosed amount. The acquisition is part of Balt’s ongoing strategy to bolster its neurovascular portfolio as well as efforts to develop a presence in the U.S., the company said. “This acquisition is a first strategic move towards transforming Balt […]
